Table 1 Baseline characteristics
| Â | All patients | SMI | SMD | ||||
|---|---|---|---|---|---|---|---|
High (n = 149, 59%) | Low (n = 102, 41%) | P | High (n = 166, 66%) | Low (n = 85, 34%) | P | ||
Age, median (range) | 63.4 ± 9.4 | 64.5 ± 9.1 | 61.7 ± 9.7 | 0.019 | 63.8 ± 9.0 | 62.6 ± 10.2 | 0.336 |
 < 65 | 137 (54.6%) | 69 (46.3%) | 68 (66.7%) | 0.002 | 88 (53.0%) | 49 (57.6%) | 0.573 |
 ≥65 | 114 (45.4%) | 80 (53.7%) | 34 (33.3%) |  | 78 (47.0%) | 36 (42.4%) |  |
Sex |  |  |  | <  0.001 |  |  | 0.582 |
 Female | 90 (35.9%) | 70 (47.0%) | 20 (19.6%) |  | 62 (37.3%) | 28 (32.9%) |  |
 Male | 161 (64.1%) | 79 (53.0%) | 82 (80.4%) |  | 104 (62.7%) | 57 (67.1%) |  |
ECOG | Â | Â | Â | 0.802 | Â | Â | 0.368 |
 0 | 26 (10.4%) | 17 (11.4%) | 9 8.8%) |  | 16 (9.6%) | 10 (11.8%) |  |
 1 | 182 (72.5%) | 107 (71.8%) | 75 (73.5%) |  | 125 (75.3%) | 57 (67.1%) |  |
 2 | 43 (17.1%) | 25 (16.8%) | 18 (17.6%) |  | 25 (15.1%) | 18 (21.2%) |  |
Location | Â | Â | Â | 0.524 | Â | Â | 0.980 |
 Head | 129 (51.4%) | 81 (54.4%) | 48 (47.1%) |  | 85 (51.2%) | 44 (51.8%) |  |
 Body | 52 (20.7%) | 29 (19.5%) | 23 (22.5%) |  | 35 (21.1%) | 17 (20.0%) |  |
 Tail | 70 (27.9%) | 39 (26.2%) | 31 (30.4%) |  | 46 (27.7%) | 24 (28.2%) |  |
Histological type | Â | Â | Â | 0.319 | Â | Â | 0.300 |
 Well diff. | 24 (9.6%) | 14 (9.4%) | 10 (9.8%) |  | 18 (10.8%) | 6 (7.1%) |  |
 Moderate diff. | 151 (60.2%) | 95 (63.8%) | 56 (54.9%) |  | 104 (62.7%) | 47 (55.3%) |  |
 Poor diff. | 41 (16.3%) | 24 (16.1%) | 17 (16.7%) |  | 24 (14.5%) | 17 (20.0%) |  |
 Unknown | 35 (13.9%) | 16 (10.7%) | 19 (18.6%) |  | 20 (12.0%) | 15 (17.6%) |  |
Number of metastatic organs | Â | Â | Â | 0.991 | Â | Â | 0.615 |
 Only one (1) | 134 (53.4%) | 79 (53.0%) | 55 (53.9%) |  | 91 (54.8%) | 43 (50.6%) |  |
 More than one (≥2) | 117 (46.6%) | 70 (47.0%) | 47 (46.1%) |  | 75 (45.2%) | 42 (49.4%) |  |
CA19–9 | 7216.2 ± 22900.6 | 5097.8 ± 15422.6 | 10310.7 ± 30549.6 | 0.114 | 6390.7 ± 21320.2 | 8828.4 ± 25767.8 | 0.454 |
| Â | Â | Â | Â | 0.512 | Â | Â | 0.034 |
 Normal | 48 (19.1%) | 31 (20.8%) | 17 (16.7%) |  | 25 (15.1%) | 23 (27.1%) |  |
 Elevated | 203 (80.9%) | 118 (79.2%) | 85 (83.3%) |  | 141 (84.9%) | 62 (72.9%) |  |
First line chemotherapy | Â | Â | Â | 0.889 | Â | Â | 0.930 |
 Gemcitabine single | 91 (36.3%) | 53 (35.6%) | 38 (37.3%) |  | 61 (36.7%) | 30 (35.3%) |  |
 Gemcitabine based chemotherapy | 160 (63.7%) | 96 (64.4%) | 64 (62.7%) |  | 105 (63.3%) | 55 (64.7%) |  |
BMI | 21.7 ± 3.1 | 21.8 ± 3.1 | 21.6 ± 3.0 | 0.666 | 21.8 ± 3.4 | 21.6 ± 2.5 | 0.514 |
Total fat area | 43.3 ± 7.8 | 144.6 ± 96.3 | 157.0 ± 85.3 | 0.298 | 125.8 ± 76.7 | 196.3± 101.6 | <  0.001 |
SMA | 122.1 ± 26.9 | 137.9 ± 20.6 | 98.9 ± 15.8 | <  0.001 | 127.2 ± 26.6 | 112.1 ± 24.6 | <  0.001 |
SMI | 46.6 ± 11.6 | 54.0 ± 8.5 | 35.7 ± 4.9 | <  0.001 | 48.8 ± 11.7 | 42.3 ± 10.2 | <  0.001 |
SMD | 43.3 ± 7.8 | 45.1 ± 7.4 | 40.7 ± 7.8 | <  0.001 | 47.7 ± 5.2 | 34.8 ± 4.4 | <  0.001 |